The PI3Kα inhibitor, alpelisib, was initially found to up-regulate ER-dependent transcriptional activity in PIK3CA-mutant ER+ breast cancer xenografts, which was circumvented by co-treatment with the selective estrogen receptor degrader (SERD), fulvestrant [60]. Here, PIK3CA is linked to breast cancer.